Revvity, Inc. (RVTY) FCF Payout Ratio: 6.42%
Is Revvity, Inc.’s FCF payout ratio high or low?
Revvity, Inc.'s FCF payout ratio of 6.42% is 90% below its 5-year average of 63.00%, near the low end of its 5-year range (2.44%–353.05%).
0.20% above its 12-month average of 6.41%.
RVTY FCF Payout Ratio Chart
RVTY Average FCF Payout Ratio Chart
RVTY Current vs Average FCF Payout Ratio Chart
RVTY FCF Payout Ratio Metrics
FCF PAYOUT RATIO
6.42%
FCF PAYOUT RATIO AVG TTM
6.41%
FCF PAYOUT RATIO AVG 3Y
92.95%
FCF PAYOUT RATIO AVG 5Y
63.00%
FCF PAYOUT RATIO AVG 10Y
39.78%
FCF PAYOUT RATIO AVG 15Y
12.94%
FCF PAYOUT RATIO AVG 20Y
16.25%
CURRENT VS TTM AVG
+0.20%
CURRENT VS 3Y AVG
-93.09%
CURRENT VS 5Y AVG
-89.81%
CURRENT VS 10Y AVG
-83.86%
CURRENT VS 15Y AVG
-50.40%
CURRENT VS 20Y AVG
-60.48%
Payout Ratio Comparison
FCF Payout Ratio
6.4%
Earnings Payout Ratio
13.5%
Dividend Yield
0.29%
FCF Yield
4.51%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $508.25M | $32.80M | 6.5% |
| 2024 | $541.65M | $34.45M | 6.4% |
| 2023 | $9.90M | $34.97M | 353.0% |
| 2022 | $594.18M | $35.34M | 5.9% |
| 2021 | $1.32B | $32.37M | 2.4% |
| 2020 | $828.54M | $31.21M | 3.8% |
| 2019 | $282.14M | $31.06M | 11.0% |
| 2018 | $217.78M | $31.01M | 14.2% |
| 2017 | $249.36M | $30.79M | 12.3% |
| 2016 | $318.91M | $30.80M | 9.7% |
| 2015 | $257.47M | $31.57M | 12.3% |
| 2014 | $252.53M | $31.62M | 12.5% |
| 2013 | $119.60M | $31.60M | 26.4% |
| 2012 | $109.76M | $31.90M | 29.1% |
| 2011 | $194.28M | $31.83M | 16.4% |
| 2010 | $130.61M | $32.99M | 25.3% |
| 2009 | $117.04M | $32.70M | 27.9% |
| 2008 | $174.52M | $33.07M | 19.0% |
| 2007 | $158.15M | $33.70M | 21.3% |
| 2006 | $82.97M | $35.45M | 42.7% |
| 2005 | $183.04M | $36.30M | 19.8% |
| 2004 | $181.80M | $35.78M | 19.7% |
| 2003 | $149.93M | $35.41M | 23.6% |
| 2002 | $33.69M | $35.28M | 104.7% |
| 2001 | $34.60M | $28.29M | 81.8% |
| 2000 | $74.95M | $27.53M | 36.7% |
| 1999 | ($227.60M) | $25.50M | N/A (Loss) |
| 1998 | ($194.90M) | $25.40M | N/A (Loss) |
| 1997 | ($13.90M) | $25.70M | N/A (Loss) |
| 1996 | ($0.30M) | $26.60M | N/A (Loss) |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
Revvity, Inc. FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Revvity, Inc. FCF Payout Ratio FAQ
- What is the FCF payout ratio for Revvity, Inc. (RVTY)?
- The FCF payout ratio for RVTY stock is 6.42%.
- Is Revvity, Inc.'s FCF payout ratio high or low?
- Revvity, Inc.'s FCF payout ratio of 6.42% is 90% below its 5-year average of 63.00%, near the low end of its 5-year range (2.44%–353.05%).
- What is the TTM average FCF payout ratio for Revvity, Inc. (RVTY)?
- The TTM average FCF payout ratio for RVTY stock is 6.41%.
- What is the 3Y average FCF payout ratio for Revvity, Inc. (RVTY)?
- The 3Y average FCF payout ratio for RVTY stock is 92.95%.
- What is the 5Y average FCF payout ratio for Revvity, Inc. (RVTY)?
- The 5Y average FCF payout ratio for RVTY stock is 63.00%.
- What is the 10Y average FCF payout ratio for Revvity, Inc. (RVTY)?
- The 10Y average FCF payout ratio for RVTY stock is 39.78%.
- What is the 15Y average FCF payout ratio for Revvity, Inc. (RVTY)?
- The 15Y average FCF payout ratio for RVTY stock is 12.94%.
- What is the 20Y average FCF payout ratio for Revvity, Inc. (RVTY)?
- The 20Y average FCF payout ratio for RVTY stock is 16.25%.
Revvity, Inc. FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2025-12-28 | 6.45% |
| 2024-12-29 | 6.36% |
| 2023-12-31 | 353.05% |
| 2022-12-31 | 5.95% |
| 2021-12-31 | 2.44% |
| 2020-12-31 | 3.77% |
| 2019-12-31 | 11.01% |
| 2018-12-31 | 14.24% |
| 2017-12-31 | 12.35% |
| 2016-12-31 | 9.66% |
| 2015-12-31 | 12.26% |
| 2014-12-31 | 12.52% |
| 2013-12-31 | 26.42% |
| 2012-12-31 | 29.07% |
| 2011-12-31 | 16.38% |
| 2010-12-31 | 25.26% |
| 2009-12-31 | 27.94% |
| 2008-12-31 | 18.95% |
| 2007-12-31 | 21.31% |
| 2006-12-31 | 42.73% |
| 2005-12-31 | 19.83% |
| 2004-12-31 | 19.68% |
| 2003-12-31 | 23.62% |
| 2002-12-31 | 104.73% |
| 2001-12-31 | 81.77% |
| 2000-12-31 | 36.74% |
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh